Home›Clinical trials›A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

Who can join
Adults 18+, are overweight, BMI 27+.
What you take
cagrilintide, given as part of the study. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The study runs about 11 months.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
Phase Phase 3Sponsor Novo Nordisk A/SDrug cagrilintideClass OtherSites 11 USEnrollment target 285

What this study is for

Primary condition: Overweight. Also studied in: Obesity.

Full scientific study title: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Key exclusion criteria

  • History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
  • Previous dosing of marketed or non-marketed amylin-based compounds.
  • Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Where this trial runs

This trial has 11 sites across 8 states. Site contacts are listed for reference. They are not screening through this trial right now.

Georgia1 site
  • Hope Clin Res & Wellness
    Conyers, Georgia
Hawaii1 site
  • East West Med Res Inst
    Honolulu, Hawaii
Illinois1 site
  • Walgreens - Store 11760
    Oak Park, Illinois
Indiana1 site
  • Midwest Inst For Clin Res
    Indianapolis, Indiana
Kentucky1 site
  • The Alliance for Multispecialty Research LLC AMR
    Lexington, Kentucky
North Carolina2 sites
  • PharmQuest
    Greensboro, North Carolina
  • KDCILM, LLC & Accellacare US, Inc.
    Wilmington, North Carolina
South Carolina1 site
  • Coastal Carolina Res Ctr
    North Charleston, South Carolina
Virginia3 sites
  • Health Res of Hampton Roads
    Newport News, Virginia
  • National Clin Res Inc.
    Richmond, Virginia
  • Selma Medical Associates
    Winchester, Virginia

Timeline

Scheduled start: August 4, 2026. Expected completion: July 6, 2027. Last updated on ClinicalTrials.gov: August 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 10, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.